Review
Biochemistry & Molecular Biology
Marcella Pesce, Luisa Seguella, Alessandro Del Re, Jie Lu, Irene Palenca, Chiara Corpetti, Sara Rurgo, Walter Sanseverino, Giovanni Sarnelli, Giuseppe Esposito
Summary: Engineered probiotics are a cutting-edge therapy in treating intestinal inflammatory diseases, offering a new strategy with therapeutically operative molecules. Traditional treatments have side effects, prompting the search for new and effective therapies as a global goal in research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Yuri Haneishi, Yuma Furuya, Mayu Hasegawa, Antonio Picarelli, Mauro Rossi, Junki Miyamoto
Summary: Inflammatory bowel disease (IBD) is a rapidly increasing inflammatory disease of the gastrointestinal tract worldwide. Recent research suggests that factors such as genetics, environment, microbiota, and immune responses are involved in its development, but the underlying causes are unclear. Dysbiosis of gut microbiota, particularly a decrease in specific genera, has been identified as a possible trigger for IBD. Improving gut microbiota and identifying specific bacterial species are crucial for understanding and treating IBD and autoimmune diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Pengfei Xu, Tengteng Lv, Shenghui Dong, Zhihao Cui, Xinyuan Luo, Baolei Jia, Che Ok Jeon, Jie Zhang
Summary: The gut microbiome is closely associated with inflammatory bowel disease (IBD). This study used bibliometric analysis to examine the association between the two terms by analyzing 3890 publications from 2000 to 2020. The results showed a rapid growth in publications on this topic since 2008, with the United States and Harvard University being the most productive country and institution, respectively. The journal Inflammatory Bowel Diseases had the highest number of published articles, while Gut was the most influential journal with the highest citation count. The most focused IBD-related topics identified through co-citation analysis were gut microbiota, metagenomics, bacterial community, fecal microbiota transplantation, probiotics, and colitis-associated colorectal cancer. Keyword cluster and burst analyses revealed that current research in the field of IBD mainly focuses on gut microbiota, metagenomics, and fecal microbiota transplantation. The literature in this field primarily explores alterations of the intestinal microbiota, microbial metabolites, and related host signaling pathways, with frequent mentions of probiotic treatment. This bibliometric analysis provides insights for future research and the development of the gut microbiome and IBD field.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2022)
Review
Nutrition & Dietetics
Tao Zhang, Jindong Zhang, Liping Duan
Summary: Genetically modified probiotics have shown efficacy in colitis models through diverse mechanisms, including modulation of gut microbiota diversity and composition, production of beneficial bacterial metabolites, regulation of inflammatory cytokine levels, modulation of oxidative stress, and improvement of intestinal barrier integrity. However, more clinical trials are needed to identify genetically modified probiotics that are both effective and safe for further clinical translation.
Article
Chemistry, Multidisciplinary
Ji-Yan Qiao, Run-Yao Zeng, Qi-Wen Chen, Diwei Zheng, Pei-Ling Hao, Xin-Hua Liu, Faqiong Zhao, Xian-Zheng Zhang
Summary: A prebiotic-probiotic living capsule (PPLC) was constructed by coculturing probiotics and Gluconacetobacter xylinus in a prebiotic-containing fermentation broth. The shaking of the culture led to the secretion of cellulose fibrils by G. xylinus, which could spontaneously encapsulate probiotics to form microcapsules under shear forces. The microcapsules, containing dense colonies of probiotics, demonstrated excellent therapeutic performance in treating enteritis mice.
Review
Gastroenterology & Hepatology
Caitlyn Hsu, Mahmoud Ghannoum, Fabio Cominelli, Luca Di Martino
Summary: Recently observed alterations of fungal load in the gastrointestinal tract of IBD patients suggest interkingdom interactions amongst different gut microbial communities. These discoveries point to the potential utilization of antifungals and probiotics that target bacteria and fungi in managing IBD.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Medicine, Research & Experimental
Shuo Yuan, Ke-Si Wang, Huan Meng, Xiao-Ting Hou, Jia-Chen Xue, Bao-Hong Liu, Wen-Wen Cheng, Jiao Li, Hua-Min Zhang, Ji-Xing Nan, Qing-Gao Zhang
Summary: Gut microbes play a specific function in intestinal diseases and have become a research hotspot in the pharmaceutical field due to their immense diversity and complexity. Inflammatory bowel disease (IBD) is a chronic inflammatory disease with an unclear etiology, but gut microbes have been found to play a critical role in its pathogenesis. Understanding the relationship between gut microbes and IBD is important for elucidating the disease's mechanism and exploring potential therapeutic approaches.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Materials Science, Multidisciplinary
Xiaowei Yang, Cuihong Li, Qinfang Wu, Qin Gan
Summary: Currently, many studies have been conducted to develop strategies for inflammatory bowel disease (IBD) treatment. However, few have explored the synergistic effects of materials and probiotics in IBD treatment. In this study, probiotics-loaded dietary fiber microspheres were prepared and their potential in IBD therapy was investigated. The microspheres loaded with probiotics showed good monodispersity, biocompatibility, and the best effects in relieving IBD symptoms and promoting body weight recovery compared to other groups, indicating the synergistic effects of probiotics and dietary fiber in IBD treatment. These results demonstrate the enormous potential of probiotics-loaded microspheres for IBD therapy.
MATERIALS RESEARCH EXPRESS
(2023)
Review
Biochemistry & Molecular Biology
Shaghayegh Baradaran Ghavami, Hamid Asadzadeh Aghdaei, Dario Sorrentino, Shabnam Shahrokh, Maryam Farmani, Fatemeh Ashrafian, Maria Pina Dore, Shahrbanoo Keshavarz Azizi Raftar, Seyed Mobin Khoramjoo, Mohammad Reza Zali
Summary: Inflammatory bowel diseases (IBDs) are immune-mediated, chronic relapsing diseases with a rising prevalence worldwide. Probiotic bacteria may impact immunomodulation by regulating dendritic cells to produce tolerogenic DCs, which could play a role in the treatment of IBD and associated conditions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Cristiano Pagnini, Maria Carla Di Paolo, Maria Giovanna Graziani, Gianfranco Delle Fave
Summary: Inflammatory bowel diseases (IBD) are chronic conditions with unknown etiology and immunomediated pathogenesis. Research on the intestinal microbiome and the vitamin D/VDR pathway have shown promising potential for novel approaches to diagnosis and treatment of IBD. Probiotic bacteria have shown more exciting results in experimental models than in clinical practice, and understanding their properties and mechanisms of action may lead to new therapeutic applications.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, Research & Experimental
Yinhua Ni, Yi Zhang, Liujie Zheng, Nianke Rong, Yuru Yang, Ping Gong, Yi Yang, Xuerong Siwu, Chenyang Zhang, Linxi Zhu, Zhengwei Fu
Summary: The effects of probiotic strains BL986 and LC122 on intestinal barrier function and gut microbiota in IBD zebrafish were investigated. The results showed that both probiotics improved intestinal mucosal barrier function and altered the composition and function of the microbiota in different IBD models. The impact of probiotics on IBD was influenced by the subtypes of IBD and the age of the zebrafish.
Review
Nutrition & Dietetics
Feilong Guo, Demin Cai, Yanwei Li, Haotian Gu, Huan Qu, Qiufang Zong, Wenbin Bao, Aoxue Chen, Hao-Yu Liu
Summary: Inflammatory bowel disease is a chronic inflammatory condition of the intestine, with gut microbiota and early-life events being implicated in its pathogenesis. Early interventions during infancy could potentially prevent the development of chronic inflammatory diseases.
FRONTIERS IN NUTRITION
(2021)
Article
Food Science & Technology
Cuijiao Feng, Weiqin Zhang, Tao Zhang, Bohai Li, Qiuwen He, Lai-Yu Kwok, Heping Zhang
Summary: This study found that oral administration of pasteurized probiotic fermented milk can significantly alleviate IBD symptoms, reduce inflammation, and restore the stability of the gut microbiota.
JOURNAL OF FUNCTIONAL FOODS
(2022)
Review
Biochemistry & Molecular Biology
Pengyu Lei, Haiyang Yu, Jiahui Ma, Jiao Du, Yimeng Fang, Qinsi Yang, Kun Zhang, Li Luo, Libo Jin, Wei Wu, Da Sun
Summary: Inflammatory bowel disease (IBD) is a serious chronic intestinal disorder that poses challenges in treatment. The emergence of cell membrane nanomaterials (CMNs) has revolutionized IBD treatment by enhancing drug properties and targeting inflammation effectively. This review explores various CMNs delivery systems for IBD treatment and proposes a hierarchically programmed delivery modality for improved efficiency and future research.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Review
Medicine, General & Internal
Flavia Maria Pavel, Cosmin Mihai Vesa, Gina Gheorghe, Camelia C. Diaconu, Manuela Stoicescu, Mihai Alexandru Munteanu, Elena Emilia Babes, Delia Mirela Tit, Mirela Marioara Toma, Simona Bungau
Summary: Inflammatory bowel disease (IBD) encompasses Crohn's disease (CD) and ulcerative colitis (UC), characterized by chronic gut inflammation due to genetic predisposition and environmental factors. Microbial studies have identified the role of gut microbiome in IBD pathophysiology, highlighting the importance of microbiome management in treatment, with probiotics and prebiotics showing beneficial effects.
Letter
Gastroenterology & Hepatology
A. A. Csontos, A. Molnar, P. Miheller
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2015)
Article
Gastroenterology & Hepatology
Anita Balint, Klaudia Farkas, Karoly Palatka, Lilla Lakner, Pal Miheller, Istvan Racz, Gabor Hegede, Aron Vincze, Gabor Horvath, Andrea Szabo, Ferenc Nagy, Zoltan Szepes, Zoltan Gabor, Ferenc Zsigmond, Agnes Zsori, Mark Juhasz, Agnes Csontos, Monika Szucs, Renata Bor, Agnes Milassin, Mariann Rutka, Tamas Molnar
JOURNAL OF CROHNS & COLITIS
(2016)
Article
Gastroenterology & Hepatology
Lorant Gonczi, Zsuzsanna Vegh, Petra Anna Golovics, Mariann Rutka, Krisztina Barbara Gecse, Renata Bor, Klaudia Farkas, Tamas Szamosi, Laszlo Bene, Beata Gasztonyi, Tunde Kristof, Laszlo Lakatos, Pal Miheller, Karoly Palatka, Maria Papp, Arpad Patai, Agnes Salamon, Gabor Tamas Toth, Aron Vincze, Edina Biro, Barbara Dorottya Lovasz, Zsuzsanna Kurti, Zoltan Szepes, Tamas Molnar, Peter L. Lakatos
JOURNAL OF CROHNS & COLITIS
(2017)
Article
Gastroenterology & Hepatology
Agnes Anna Csontos, Andrea Molnar, Zsolt Piri, Erzsebet Palfi, Pal Miheller
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
(2017)
Article
Medicine, General & Internal
Rutka Mariann, Balint Anita, Farkas Klaudia, Palatka Karoly, Lakner Lilla, Miheller Pal, Racz Istvan, Hegede Gabor, Vincze Aron, Horvath Gabor, Szabo Andrea, Nagy Ferenc, Szepes Zoltan, Gabor Zoltan, Zsigmond Ferenc, Zsori Agnes, Juhasz Mark, Csontos Agnes, Szucs Monika, Bor Renata, Milassin Agnes, Molnar Tamas
Article
Nutrition & Dietetics
A. Molnar, A. A. Csontos, I. Kovacs, A. D. Anton, E. Palfi, P. Miheller
EUROPEAN JOURNAL OF CLINICAL NUTRITION
(2017)
Review
Pharmacology & Pharmacy
Anita Balint, Mariann Rutka, Zsuzsanna Vegh, Zsuzsanna Kurti, Krisztina B. Gecse, Janos Banai, Laszlo Bene, Beata Gasztonyi, Tunde Kristof, Laszlo Lakatos, Pal Miheller, Karoly Palatka, Arpad Patai, Agnes Salamon, Tamas Szamosi, Zoltan Szepes, Gabor Tamas Toth, Aron Vincze, Renata Bor, Agnes Milassin, Anna Fabian, Ferenc Nagy, Martin Kolar, Martin Bortlik, Dana Duricova, Veronika Hruba, Martin Lukas, Katarina Mitrova, Karin Malickova, Milan Lukas, Peter L. Lakatos, Tamas Molnar, Klaudia Farkas
EXPERT OPINION ON DRUG SAFETY
(2017)
Article
Gastroenterology & Hepatology
Lorant Gonczi, Krisztina B. Gecse, Zsuzsanna Vegh, Zsuzsanna Kurti, Mariann Rutka, Klaudia Farkas, Petra A. Golovics, Barbara D. Lovasz, Janos Banai, Laszlo Bene, Bea Gasztonyi, Tunde Kristof, Laszlo Lakatos, Pal Miheller, Ferenc Nagy, Karoly Palatka, Maria Papp, Arpad Patai, Agnes Salamon, Tamas Szamosi, Zoltan Szepes, Gabor T. Toth, Aron Vincze, Balazs Szalay, Tamas Molnar, Peter L. Lakatos
INFLAMMATORY BOWEL DISEASES
(2017)
Article
Medicine, General & Internal
Molnar Andrea, Csontos Agnes Anna, Dako Sarolta, Hencz Rita, Anton Daniel Aron, Palfi Erzsebet, Miheller Pal
Article
Biotechnology & Applied Microbiology
Renata Bor, Anna Fabian, Maria Matuz, Zoltan Szepes, Klaudia Farkas, Pal Miheller, Tamas Szamosi, Aron Vincze, Mariann Rutka, Kata Szanto, Anita Balint, Ferenc Nagy, Agnes Milassin, Tibor Toth, Ferenc Zsigmond, Judit Bajor, Katalin Mullner, Lilla Lakner, Maria Papp, Agnes Salamon, Gabor Horvath, Krisztina Sarang, Eszter Schafer, Patricia Sarlos, Karoly Palatka, Tamas Molnar
EXPERT OPINION ON BIOLOGICAL THERAPY
(2020)
Letter
Gastroenterology & Hepatology
Anett Santa, Kata Judit Szanto, Patricia Sarlos, Pal Miheller, Klaudia Farkas, Tamas Molnar
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2020)
Article
Gastroenterology & Hepatology
Raja Atreya, Laurent Peyrin-Biroulet, Andrii Klymenko, Monica Augustyn, Igor Bakulin, Dusan Slankamenac, Pal Miheller, Antonio Gasbarrini, Xavier Hebuterne, Karin Arnesson, Thomas Knittel, Jan Kowalski, Markus F. Neurath, William J. Sandborn, Walter Reinisch
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2020)
Article
Gastroenterology & Hepatology
Lorant Gonczi, Kata Szanto, Klaudia Farkas, Tamas Molnar, Tamas Szamosi, Eszter Schafer, Petra A. Golovics, Laszlo Barkai, Livia Lontai, Barbara Lovasz, Mark Juhasz, Arpad Patai, Krisztina Sarang, Aron Vincze, Patricia Sarlos, Alexandra Farkas, Zsolt Dubravcsik, Tamas G. Toth, Pal Miheller, Akos Ilias, Peter L. Lakatos
Summary: The clinical efficacy, drug sustainability, dose intensification, and therapeutic drug monitoring of ustekinumab therapy in patients with Crohn's disease were evaluated in this prospective, nationwide, multicenter cohort study. The study found that ustekinumab showed favorable drug sustainability and clinical efficacy in patients with severe disease phenotype and previous anti-tumor necrosis factor failure. However, frequent dose intensification was required.
DIGESTIVE AND LIVER DISEASE
(2022)
Article
Biology
Eva Anna Piros, Akos Szabo, Fanni Rencz, Valentin Brodszky, Norbert Wikonkal, Pal Miheller, Miklos Horvath, Peter Hollo
Summary: This study found that anti-interleukin-17 therapy does not significantly affect body composition parameters in severe psoriatic patients, but can improve lipid and inflammatory parameters, potentially benefiting the cardiometabolic status of patients, especially high-risk obese individuals with psoriasis.
Article
Biotechnology & Applied Microbiology
Anita Balint, Mariann Rutka, Martin Kolar, Martin Bortlik, Dana Duricova, Veronika Hruba, Martin Lukas, Katarina Mitrova, Karin Malickova, Milan Lukas, Zoltan Szepes, Ferenc Nagy, Karoly Palatka, Szilvia Lovas, Zsuzsanna Vegh, Zsuzsanna Kurti, Agnes Csontos, Pal Miheller, Tibor Nyari, Renata Bor, Agnes Milassin, Anna Fabian, Kata Szanto, Peter L. Lakatos, Tamas Molnar, Klaudia Farkas
EXPERT OPINION ON BIOLOGICAL THERAPY
(2018)
